A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia

다국어 초록 (Multilingual Abstract)

We previously demonstrated that atherogenic Ldlr−/−Apobec1−/− (LDb) double knockout mice lacking both low-density lipoprotein receptor (LDLR) and apolipoprotein B mRNA-editing catalytic polypeptide-1 (Apobec1) had increased serum IL-17 levels, with T cell programming shifted towards Th17 cells. In this study, we assessed the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in T cell programming and atherogenesis. We deleted the Pcsk9 gene from LDb mice to generate Ldlr−/−Apobec1−/−Pcsk9−/− (LTp) triple knockout mice. Atherosclerosis in the aortic sinus and aorta were quantitated. Lymphoid cells were analyzed by flow cytometry, ELISA and real-time PCR. Despite of dyslipidemia, LTp mice developed barely detectable atherosclerotic lesions. The IL-17, was very low in plasma and barely detectable in the aortic sinus in the LTp mice. In the spleen, the number of CD4+CD8− cells and splenocytes were much lower in the LDb mice than LTp mice, whereas, the IL-17-producing cells of γδTCR+ T cells and effector memory CD4+ T cells (CD44hiCD4+) in the spleen were significantly higher in the LDb mice than in the LTp mice. The Rorc mRNA expression levels were elevated in LDb mice compared to LTp mice. When re-stimulated with an anti-CD3 Ab, CD44hiCD4+ T cells from LDb mice secreted more IL-17 than those from LTp mice. T cells from LDb mice (with PCSK9) produce more IL-17 at basal and stimulated conditions when compared with LTp mice (without PCSK9). Despite the dyslipidemic profile and the lack of LDLR, atherogenesis is markedly reduced in LTp mice. These results suggest that PCSK9 is associated with changes in T cell programming that contributes to the development of atherosclerosis.

참고문헌 (Reference)

1 Gisterå A, "Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway" 5 (5): 2013

2 ong BW, "The biological role of inflammation in atherosclerosis" 28 : 631-641, 2012

3 Butcher MJ, "The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment" 110 : 675-687, 2012

4 Damsker JM, "Th1 and Th17 cells: adversaries and collaborators" 1183 : 211-221, 2010

5 Buono C, "T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses" 102 : 1596-1601, 2005

6 Proto JD, "Regulatory T cells promote macrophage efferocytosis during inflammation resolution" 49 : 666-677.e6, 2018

7 Meng X, "Regulatory T cells in cardiovascular diseases" 13 : 167-179, 2016

8 Kimura T, "Regulatory CD4+ T cells recognize major histocompatibility complex class II molecule-restricted peptide epitopes of apolipoprotein B" 138 : 1130-1143, 2018

9 Sharotri V, "Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)" 287 : 19266-19274, 2012

10 Paigen B, "Quantitative assessment of atherosclerotic lesions in mice" 68 : 231-240, 1987

11 Tangirala RK, "Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice" 36 : 2320-2328, 1995

12 Sun H, "Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor" 32 : 1585-1595, 2012

13 Canuel M, "Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)" 8 : e64145-, 2013

14 Libby P, "Progress and challenges in translating the biology of atherosclerosis" 473 : 317-325, 2011

15 Lim H, "Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo" 40 : 153-165, 2014

16 Yang W, "Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism" 531 : 651-655, 2016

17 Park SW, "Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver" 279 : 50630-50638, 2004

18 Kysenius K, "PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling" 69 : 1903-1916, 2012

19 Liu A, "PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque" 193-210, 2018

20 Hilvo M, "PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions" 269 : 159-165, 2018

21 Demers A, "PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver" 35 : 2517-2525, 2015

22 Labonté P, "PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression" 50 : 17-24, 2009

23 Sun H, "PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction" 59 : 207-223, 2018

24 Shan L, "PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide" 375 : 69-73, 2008

25 Maxwell KN, "Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment" 102 : 2069-2074, 2005

26 Tabas I, "Monocyte-macrophages and T cells in atherosclerosis" 47 : 621-634, 2017

27 Hobbs HH, "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia" 1 : 445-466, 1992

28 Daugherty A, "Modes of defining atherosclerosis in mouse models: relative merits and evolving standards" 573 : 1-15, 2009

29 Nus M, "Marginal zone B cells control the response of follicular helper T cells to a high-cholesterol diet" 23 : 601-610, 2017

30 Taleb S, "Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis" 206 : 2067-2077, 2009

31 Momtazi-Borojeni AA, "Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system" 283 : 69-78, 2019

32 Nischal H, "Long-term expression of apolipoprotein B mRNA-specific hammerhead ribozyme via scAAV8.2 vector inhibits atherosclerosis in mice" 2 : e125-, 2013

33 Li G, "Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-κB/HIF-1α pathway" 53 : 227-236, 2013

34 Mai J, "Interleukin-17A promotes aortic endothelial cell activation via transcriptionally and post-translationally activating p38 mitogen-activated protein kinase (MAPK) pathway" 291 : 4939-4954, 2016

35 Danzaki K, "Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice" 32 : 273-280, 2012

36 Numasaki M, "Interleukin-17 promotes angiogenesis and tumor growth" 101 : 2620-2627, 2003

37 Eid RE, "Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells" 119 : 1424-1432, 2009

38 Billon C, "Inhibition of RORα/γ suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation" 5 : 997-1005, 2016

39 Cheng X, "Inhibition of IL-17A in atherosclerosis" 215 : 471-474, 2011

40 Erbel C, "Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice" 183 : 8167-8175, 2009

41 Manduteanu I, "Inflammation in atherosclerosis: a cause or a result of vascular disorders" 16 : 1978-1990, 2012

42 Libby P, "Inflammation in atherosclerosis" 32 : 2045-2051, 2012

43 Singh U, "Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice" 106 : 421-432, 2004

44 Surls J, "Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response" 7 : e38733-, 2012

45 Ge S, "Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by interleukin-17A" 113 : 965-974, 2013

46 Libby P, "Immune effector mechanisms implicated in atherosclerosis: from mice to humans" 38 : 1092-1104, 2013

47 Jin W, "IL-17 cytokines in immunity and inflammation" 2 : e60-, 2013

48 Korn T, "IL-17 and Th17 cells" 27 : 485-517, 2009

49 Proto JD, "Hypercholesterolemia induces T cell expansion in humanized immune mice" 128 : 2370-2375, 2018

50 Dutta R, "Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes" 169 : 51-62, 2003

51 Mak S, "Differential expression of genes in the calcium-signaling pathway underlies lesion development in the LDb mouse model of atherosclerosis" 213 : 40-51, 2010

52 Daugherty A, "Development of experimental designs for atherosclerosis studies in mice" 36 : 129-138, 2005

53 Adam D, "Ceramide: does it matter for T cells" 23 : 1-4, 2002

54 Stepanova H, "CD4+ and γδTCR+ T lymphocytes are sources of interleukin-17 in swine" 58 : 152-157, 2012

55 Smith E, "Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice" 121 : 1746-1755, 2010

56 Brauner S, "Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content" 114 : 158-167, 2018

57 Ryu H, "Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27" 19 : 583-593, 2018

58 Gaddis DE, "Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis" 9 : 1095-, 2018

59 Nordlohne J, "Aggravated atherosclerosis and vascular inflammation with reduced kidney function depend on interleukin-17 receptor a and are normalized by inhibition of interleukin-17A" 3 : 54-66, 2018

60 Krauzová E, "Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women" 250 : 151-157, 2016

61 Gutcher I, "APC-derived cytokines and T cell polarization in autoimmune inflammation" 117 : 1119-1127, 2007